Data Collection in Lutetium Treated Prostate Cancer: Recording of Progression and Tumor Characteristics

Data Collection in Lutetium Treated Prostate Cancer: Recording of Progression and Tumor Characteristics

This prospective study aims to collect data and blood biomarkers from patients undergoing Lu-PSMA therapy at the Erasmus MC. In doing so, it will provide real-world efficacy and safety data on the drug, gather dosimetry data and explore putative biomarkers to identify patients who most benefit from Lu-PSMA treatment.

Inclusion Criteria:

• Participants should be at least 18 years old.
• Participants should be able to understand the written information and be able to provide informed consent.
• Participants are planned to start treatment with Lu-PSMA as a part of regular clinical care.

Exclusion Criteria:

None applicable